Continuous Glucose Monitoring Clinical Trial
Official title:
Markers for Glycaemic Control and Continuous Glucose Monitoring in Persons With Type 2 Diabetes on Peritoneal Dialysis
Verified date | September 2020 |
Source | Rigshospitalet, Denmark |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The aim is to investigate the correlation between mean glucose measured by continuous glucose monitoring (CGM) and mean glucose estimated from glycated haemoglobin A1c (HbA1c) in persons with type 2 diabetes undergoing peritoneal dialysis compared with patients with type 2 diabetes and normal renal function. Furthermore, the aim is to compare CGM and HbA1c with glycated albumin and fructosamine.
Status | Completed |
Enrollment | 54 |
Est. completion date | September 3, 2020 |
Est. primary completion date | September 3, 2020 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion criteria for case group (on peritoneal dialysis with type 2 diabetes): - Type 2 diabetes* - BMI 17.5-50 kg/m2 - Receiving antidiabetic treatment - Peritoneal dialysis treatment for a minimum of 3 months Exclusion criteria for case group (on peritoneal dialysis with type 2 diabetes): - Type 1 diabetes - Acute or chronic pancreatitis - Intermittent treatment with steroid during study period (defined as more than two days) - Haemoglobin < 5.5 mmol / l - Hypertriglyceridemia (= 10mmol / L) - Hyperbilirubinemia (= 35 µmol / L) - Pregnant or breast-feeding - Blood transfusion within the last 3 months - Blood transfusion during the investigation period - Splenectomy - High alcohol consumption (defined as more than 21 units per week) - Vitamin E supplement - Ribavirin treatment - Interferon Alpha treatment - Positive for haemoglobinopathy (examined for haemoglobinopathy if patients come from Africa, Mediterranean, Middle East, Iran, Iraq, India, Pakistan or Southeast Asia) - Severe infections Inclusion criteria for control group (type 2 diabetes and normal renal function): - Type 2 diabetes* - BMI 17.5-50 kg / m2 - Receiving antidiabetic treatment - eGFR > 60 ml/min/1.73m2 - Urine Albumin-to-Creatinine Ratio < 300mg/g Exclusion criteria for control group (type 2 diabetes and normal renal function): - Type 1 diabetes - Acute or chronic pancreatitis - Intermittent treatment with steroid during study period - Haemoglobin <7.3 mmol / l for women - Haemoglobin <8.3 mmol / l for men - Hypertriglyceridemia (= 10mmol / L) - Hyperbilirubinemia (= 35 µmol / L) - Pregnant or breast-feeding - Blood transfusion within the last 3 months - Blood transfusion during the investigation period - Splenectomy - High alcohol consumption (defined as more than 21 units per week) - Vitamin E supplement - Ribavirin - Interferon Alpha treatment - Positive for haemoglobinopathy (examined for haemoglobinopathy if patients come from Africa, Mediterranean, Middle East, Iran, Iraq, India, Pakistan or Southeast Asia) - Severe infections *Inclusion with diagnosis of type 2 diabetes was defined as ongoing antidiabetic treatment and previously diagnosed with type 2 diabetes according to the following criteria: - A random venous plasma glucose concentration = 11.1 mmol/l or - A fasting plasma glucose concentration = 7.0 mmol/l (whole blood = 6.1 mmol/l) or - Two hour plasma glucose concentration = 11.1 mmol/l two hours after 75g anhydrous glucose in an oral glucose tolerance test or - HbA1c above 48 mmol/mol |
Country | Name | City | State |
---|---|---|---|
Denmark | Herlev Hospital | Copenhagen | |
Denmark | Rigshospitalet department of endocrinology | Copenhagen | |
Denmark | Hillerød Hospital | Hillerød | |
Denmark | Rigshospitalet department of nephrology | København Ø | |
Denmark | Roskilde Hospital | Roskilde |
Lead Sponsor | Collaborator |
---|---|
Rigshospitalet, Denmark | Herlev Hospital, Hillerod Hospital, Denmark, Steno Diabetes Center Copenhagen, Zealand University Hospital |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | HbA1c evaluated by the total mean glucose from continuous glucose monitoring | Difference between the two groups in the ratio of mean glucose measured by continuous glucose monitoring (measured over 16 days) divided by the estimated mean blood glucose from HbA1c (measured at the final visit). For each person at least 12 days of CGM must be completed. | 16 days | |
Secondary | Glycated albumin | Correlation between mean glucose from continuous glucose monitoring (measured over 16 days) and glycated albumin ((%) measured at the final visit). | 16 days | |
Secondary | Fructosamine | Correlation between mean glucose from continuous glucose monitoring (measured over 16 days) and fructosamine ((µmol/l) measured at the final visit). | 16 days | |
Secondary | Standard deviation | Standard deviation for glycaemic variability measured by continuous glucose monitoring in both groups. | 16 days | |
Secondary | Coefficient variation | Coefficient variation for glycaemic variability measured by continuous glucose monitoring in both groups. | 16 days | |
Secondary | Low Blood Glucose Index | Low Blood Glucose Index for glycaemic variability measured by continuous glucose monitoring in both groups. Is a risk index for predicting hypoglycaemia. | 16 days | |
Secondary | High Blood Glucose Index | High Blood Glucose Index for glycaemic variability measured by continuous glucose monitoring in both groups. Is a risk index for predicting hyperglycaemia. | 16 days | |
Secondary | Time in hypoglycaemic range below 3.0 mmol/l | Time in hypoglycaemic range(%) below 3.0 mmol/l evaluated by continuous glucose monitoring . | 16 days | |
Secondary | Time in hypoglycaemic range below 3.9 mmol/l to 3.0 mmol/l | Time in hypoglycaemic range(%) below 3.9 mmol/l to 3.0 mmol/l evaluated by continuous glucose monitoring . | 16 days | |
Secondary | Time in hyperglycaemic range above 10.0 mmol/l | Time in hyperglycaemic range(%) above 10.0 mmol/l evaluated by continuous glucose monitoring . | 16 days | |
Secondary | Time in hyperglycaemic range above 13.9 mmol/l | Time in hyperglycaemic range(%) above 13.9 mmol/l evaluated by continuous glucose monitoring | 16 days | |
Secondary | Hypoglycaemic events | Beginning of a CGM event is defined as a reading below the threshold for at least 15 min for either a value below 3.0 mmol/l or between 3.9 mmol/l to 3.0 mmol/l. The end of a CGM event is defined as a reading for 15 min above 3.9 mmol/l. | 16 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04099043 -
Cascade CGM 15-day Performance Assessment
|
N/A | |
Recruiting |
NCT05441982 -
Saccharin and Acesulfame Potassium Consumption and Glucose Homeostasis in Older Adults With Prediabetes
|
N/A | |
Completed |
NCT05038761 -
A Study to Learn How Well a Monitoring System Called Continuous Glucose Monitoring (CGM) Which Measures Glucose on an Ongoing Basis Works and How Safe it is in Chinese Patients in Usual Practice
|
||
Completed |
NCT01714895 -
Effect of Different Plasma Insulin Levels on the Accuracy of Continuous Subcutaneous Glucose Monitoring
|
N/A | |
Not yet recruiting |
NCT05531838 -
Prediabetes Management
|
N/A | |
Active, not recruiting |
NCT06226948 -
Using the Visualization for Lifestyle Change in Patients at Risk of Cardiovascular Diseases
|
N/A | |
Completed |
NCT05348928 -
A Pilot Study of the Feasibility and Accuracy of the TrueVie CGM System - A Non-Significant Risk Study
|
||
Active, not recruiting |
NCT05336214 -
Implementing Continuous Glucose Monitoring in Primary Care for Patients With Diabetes
|
N/A | |
Terminated |
NCT03067480 -
Comparison of 3 Versus 6-Month Use of CGMS in Non-Insulin Using T2DM Patients
|
N/A | |
Completed |
NCT04558710 -
The Effect of Frequent Continuous Glucose Monitoring Use on Glucose Variability in Preschoolers With Type 1 Diabetes
|
||
Withdrawn |
NCT04385862 -
The Use of a Continuous Glucose Monitoring System (Dexcom G6) in Hospitalized Patients for Acute Care
|
||
Not yet recruiting |
NCT06436326 -
The Impact of Continuous Glucose Monitoring on Maternal and Infant's Outcomes in Gestational Diabetes
|
N/A | |
Not yet recruiting |
NCT04172116 -
Continuous Glucose Monitoring (CGM) After Surgical Variations of the Roux-en-y Gastric Bypass
|
||
Completed |
NCT01883622 -
Glucose Variability in Pregnancy Complicated by Diabetes
|
N/A | |
Recruiting |
NCT05947916 -
Real Time Continuous Glucose Monitoring System in T2DM With Pregnacy
|
N/A | |
Active, not recruiting |
NCT05564481 -
Research on Optimizing the Use of Technology With Education
|
N/A | |
Recruiting |
NCT06400641 -
Study on the Feasibility of Continuous Glucose Monitoring(CGM) for Improving Blood Glucose Control in Severe Patients
|
||
Recruiting |
NCT04099550 -
Effect of Real-time Continuous Glucose Monitoring System in Overweight or Obese Adults With Prediabetes
|
N/A | |
Not yet recruiting |
NCT04397965 -
Cascade Continuous Glucose Monitor (CGM) 15-Day US Performance Assessment
|
N/A | |
Completed |
NCT02942069 -
Reproducibility of Glucose Fluctuations by Standardized Exercise for Patients With Type 1 Diabetes - a Method Study Based on Continuous Glucose Monitoring
|